Global pharmaceutical company Lupin Limited has received approval from the US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Sodium Zirconium Cyclosilicate for Oral Suspension in 5 g and 10 g packets. The US FDA has approved the product as bioequivalent to Lokelma® for Oral Suspension, the reference listed drug marketed by AstraZeneca Pharmaceuticals LP. Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension is indicated for the treatment of hyperkalemia in adults.
Hyperkalemia is a condition in which potassium levels in the blood become abnormally high. It can occur in people with certain kidney, heart or other medical conditions and may require timely treatment to reduce the risk of serious complications.According to IQVIA data for the 12 months ended June 2026, the US market for Sodium Zirconium Cyclosilicate for Oral Suspension, based on the reference product Lokelma®, was estimated at USD 568 million.
The approval strengthens Lupin’s portfolio in the US market and adds another product to its growing range of complex and differentiated pharmaceutical offerings. The company continues to focus on expanding access to medicines through its product development and regulatory capabilities.
Lupin has a broad presence across India, the United States, other developed markets and emerging markets, with its products available in more than 100 countries. The company’s portfolio includes generics, complex generics, specialty medicines and biosimilars.
The company has established strong positions in the US and Indian markets across key therapeutic areas, including cardiovascular, respiratory, gastrointestinal and women’s health.
Lupin operates 15 manufacturing facilities supported by six research centres and a workforce of more than 26,000 employees worldwide. Its research and manufacturing network supports the development and supply of medicines across multiple markets. Beyond pharmaceuticals, Lupin has expanded its presence across the healthcare ecosystem through diagnostics, digital health initiatives, patient support programmes and disease management services.
The company also continues to focus on sustainability as part of its business strategy, with initiatives aimed at improving operational efficiency and supporting responsible growth. The latest US FDA approval further expands Lupin’s product portfolio in the United States and supports the company’s focus on providing medicines across important areas of healthcare.
Lupin Limited is a global pharmaceutical company headquartered in Mumbai, India. The company develops and manufactures medicines across generics, complex generics, specialty products and biosimilars. With operations across major global markets and a workforce of more than 26,000 professionals, Lupin continues to focus on innovation, manufacturing capabilities and expanding access to healthcare.